<DOC>
	<DOC>NCT00929864</DOC>
	<brief_summary>The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive</brief_summary>
	<brief_title>Abatacept Versus Adalimumab Head-to-Head</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria Methotrexate failure Naive to RA biologics ≤5 years duration of disease Disease Activity Score28 Creactive protein (DAS28 CRP) ≥ 3.2 Willingness to selfinject subcutaneous (SC) drug Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)blocking agents History of active or chronic hepatitis Cancer in the last 5 years History of severe chronic or recurrent bacterial or viral infections Risk of tuberculosis Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>